.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AA22_Abetimus.Abetimus .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AA22_Abetimus.Abetimus| name: | Abetimus | |
| ATC code: | L04AA22 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 400 | mg |
| volume of distribution: | 4 | L |
| clearance: | 0.2 | L/h |
| other parameters in model implementation | ||
Abetimus is a synthetic double-stranded oligonucleotide that acts as an immunosuppressive agent by inhibiting the production of anti-double stranded DNA antibodies. It was developed for the treatment of systemic lupus erythematosus (SLE) but was never approved, and its development has been discontinued.
Estimated PK parameters based on pharmacological class and physicochemical properties, as no published clinical pharmacokinetic data are available for abetimus in humans.